ARTINI HLDG (00789) and Guangzhou Baiyunshan Pharmaceutical Holdings sign a strategic cooperation agreement to jointly develop products in the health industry and expand markets.

ARTINI HLDG (00789) announced that on September 19, 2025, the company signed a strategic cooperation agreement with Guangzhou Baiyunshan Pharmaceutical Holdings Weiyi Industrial Co., Ltd. (Guangzhou Baiyunshan Pharmaceutical Holdings Weiyi) to jointly develop products in the field of health and expand the market (strategic cooperation). The cooperation period is one year. Guangzhou Baiyunshan Pharmaceutical Holdings Weiyi is a subsidiary of Guangzhou Baiyunshan Pharmaceutical Holdings Group Co., Ltd., a company listed on the Shanghai Stock Exchange (600332.SH) and the Main Board of the Hong Kong Stock Exchange (00874), focusing on the health industry. According to the cooperation agreement, the group and Guangzhou Baiyunshan Pharmaceutical Holdings Weiyi propose the following strategic cooperation categories: 1. Joint product development: Both parties will jointly research and develop innovative products in the field of health, such as natural plant extracts, functional health products, personal care products, etc. 2. Market expansion: Both parties plan to promote the jointly developed products and related existing products to overseas markets. Guangzhou Baiyunshan Pharmaceutical Holdings Weiyi will provide brand marketing support to the group, including brand strategy, brand strategy, trademark authorization, and provide technical consultation, product promotion, and marketing guidance related to the sales and market promotion of health products for the group. In recent years, the group has been actively expanding its sales business in beauty and health products. The strategic cooperation intention reached with Guangzhou Baiyunshan Pharmaceutical Holdings Weiyi this time is in line with the group's business development strategy and long-term layout in the health industry. The Board believes that this strategic cooperation can leverage the advantages of the group's international market and sales platform with the technology, brand, and product advantages of Guangzhou Baiyunshan Pharmaceutical Holdings Weiyi to achieve synergies. This move is expected to enrich the group's product portfolio, enhance its core competitiveness in the health field, and open up new sources of income. Therefore, the Board believes that signing a cooperation agreement with Guangzhou Baiyunshan Pharmaceutical Holdings Weiyi is in the overall interest of the company and its shareholders.